Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020631 · ClinicalTrials.gov registry record · NA
Pirfenidone in Treating Patients With Fibrosis Caused by Radiation Therapy for Cancer
A NA study of Radiation Fibrosis, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- NA
- Development phase
- 1
- Study location
NCT00020631: Completed NA study of Radiation Fibrosis, sponsored by National Cancer Institute (NCI).
NCT00020631 is a NA study of Radiation Fibrosis that has completed, run by National Cancer Institute (NCI). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00020631, a NA study of Radiation Fibrosis, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- NA
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Pirfenidone may prevent or lessen fibrosis caused by radiation therapy. PURPOSE: Pilot trial to study the effectiveness of pirfenidone in preventing or lessening fibrosis in patients who have undergone radiation therapy for cancer.
Conditions Studied
Interventions
- DRUG pirfenidone
Study Locations (1)
Maryland
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support - Bethesda
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-10 |
| Est. Completion | 2007-10 |
| Phase | NA |
What the finished NCT00020631 record still lists
NCT00020631 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Radiation Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which pirfenidone is the first listed.
NCT00020631 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00020631 about?
NCT00020631 is a clinical study titled "Pirfenidone in Treating Patients With Fibrosis Caused by Radiation Therapy for Cancer". RATIONALE: Pirfenidone may prevent or lessen fibrosis caused by radiation therapy. PURPOSE: Pilot trial to study the effectiveness of pirfenidone in preventing or lessening fibrosis in patients who have undergone radiation therapy for cancer.
What is the current status of trial NCT00020631?
This trial is currently completed. It is a NA study. The study started on 2001-10. Estimated completion is 2007-10.
What conditions does trial NCT00020631 study?
This clinical trial studies the following conditions: Radiation Fibrosis.
What interventions are being tested in trial NCT00020631?
The interventions under investigation include: pirfenidone (DRUG).
Who is sponsoring clinical trial NCT00020631?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00020631 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Radiation Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia